LACTB and infection: Over the 31-day stay, the patient received amoxicillin-clavulanate, a penicillin-class antibiotic combined with a beta-lactamase inhibitor that broadens the antimicrobial spectrum; cefepime, a fourth-generation cephalosporin with activity against both Gram-negative and Gram-positive organisms; and meropenem, a carbapenem considered a “last-resort” treatment against infections by Gram-positive and Gram-negative bacteria, due to its resistance to extended-spectrum beta-lactamases (ESBLs) (Huttner et al., 2020; Meurant et al., 2021; Raza et al., 2021).